Arcadia Biosciences: Capuchin reports 15.7% stake
The reported position represents 15.7% of Arcadia Biosciences’ outstanding common shares, with shared voting and disposition authority.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Arcadia Biosciences, Inc. (RKDA) is the issuer in a Schedule 13G reporting that MJL Manager LLC, Michael Liu, and Capuchin Capital Fund LP each report beneficial ownership of 378,740 common shares, representing 15.7% of the class. Each reports shared voting and dispositive power over 378,740 shares, with no sole voting or dispositive power. MJL is the fund’s general partner; Michael Liu is MJL’s sole control person and has authority to direct voting and disposition of shares held by the fund. The reporting persons state that reporting shared power is not an admission of beneficial ownership of shares attributed to another reporting person, and disclaim beneficial ownership except to the extent of each person’s actual pecuniary interest. The 15.7% calculation uses 2,409,211 shares outstanding, as reported by Arcadia in its Form 10-Q filed August 13, 2026.
Key Figures
Key Terms
beneficial ownership regulatory
actual pecuniary interest regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.